News

CAARE is excited to present our hard-hitting report “From Trauma to Treatment: Addressing the crisis in treating Post-Traumatic Stress Disorder.”

In comprehensive detail we expose the shocking failures of PTSD research involving animals and provide well-researched information on how to spare the lives of millions of animals by providing effective, scientifically-validated treatments to those who suffer from Post-Traumatic Stress Disorder (PTSD).

Thousands of animals are tragically being killed for research into COVID-19.  Yet, as CAARE has previously shown, animal models consistently fail to predict human outcomes and there is an urgent need to rely on superior, non-animal alternatives to end this pandemic.

As the deadly coronavirus spreads exponentially across the globe, researchers are racing to develop a vaccine that will bring the pandemic to a halt.

A surprisingly novel yet promising alternative to traumatic psychology experiments on animals is to replace them with artificial intelligence and robots.

Cognitive psychologist Elan Barenholtz and computer scientist William Hahn, both at Florida Atlantic University, have developed lap-top size robots, equipped with artificial intelligence. With a camera that senses the environment, the robots are guided by internal computers using neural networks based on the mechanics of the human brain. 

In a stunning breakthrough last month, CAARE learned that egregious cat brain experiments at the State University of NY College of Optometry (SUNY) were ended due to our campaign.

I have some incredibly wonderful news to share with you today.

We’ve learned that decades of egregious experiments on cats and kittens at the State University of New York College of Optometry (SUNY) have ended as a result of CAARE’s campaign!

Parkinson's Disease is a neurological disorder primarily caused by degeneration of specific neurons that results in tremors, rigidity and loss of voluntary movement. Like many other devastating neurological diseases, treatment is limited and there is no cure. Millions of dollars have been invested over decades to study animal models with no real success.

Now a company in Luxembourg, Organo-Therapeutics, is directing its focus on utilizing human stem cell technologies to create “mini-brains” to develop treatments for Parkinson’s Disease.  Founders Javier Jarazo, PhD and Jens Schwamborn PhD, a professor at the University of Luxembourg, hope to demonstrate that disease research can be done without the use of animals.

Computational modeling is an exciting area of biomedical research that uses computers to simulate biological systems, referred to as “in silico” research.

In July French company, Dassault Systèmes, a pioneer in 3D design software and creator of the Living Heart Project, announced that its collaboration with the U.S. Food and Drug Administration (FDA) will be extended for another 5 years.  This partnership, begun in 2014, focuses on in silico testing for potential therapeutic devices to treat heart disease.

The latest innovation in organs-on-chips is the pancreas-on-a-chip, which incorporates 3D organoid technology to enhance the chip’s performance. It was developed by scientists at the Cincinnati Children’s Hospital Medical Center to study life-threatening cystic-fibrosis-related diabetes, a common complication for cystic fibrosis (CF) patients.  

The study, published in Nature Communications, finds that this in-vitro model of the human pancreas has enormous potential to elucidate the causes of CF related diabetes, while also noting the failures and limitations of previous animal research.

Last week, a New York judge determined that CAARE’s lawsuit against the State University of NY College of Optometry (SUNY) can move forward by denying SUNY's motion to dismiss the case.

SUNY had tried to dispel our suit by asserting frivolous claims that had no foundation in fact or in the law. Their real goal was to block CAARE from obtaining the full details about terribly invasive and injurious experiments on cats that expose their brains, confine them in devices and put them through lengthy vision testing trials.